Low initial expression of LAMP2 was a predictor of refractoriness in patients with MDS or AML, and decreasing levels of LAMP2 during AZA treatment led to the development of resistance and a compensatory increase in autophagy. This evidence concerns the gene LAMP2 and myelodysplastic syndrome.